Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Axitinib (AXITINIB) is an oral, potent, and selective inhibitor of vascular endothelial
growth factor receptors 1, 2, and 3 which has achieved objective response rate of 44.2% in
phase II study in cytokine-refractory metastatic renal-cell cancer patients.
Pre-surgical treatment with Axitinib could allow a substantial proportion of patients with
large organ confined tumors to benefit from NSS.
The Objective is to determine the efficacy of Axitinib administered prior to surgery in
patients with large organ confined tumors not primarily suitable for NSS (cT2aNoNxM0) for
shifting from a radical nephrectomy indication to a nephron sparing procedure.